Novo's Human Growth Hormone Patent Ruled Invalid, Unenforceable

Law360, New York (August 6, 2004, 12:00 AM EDT) -- A federal district court has found Danish drug maker Novo Nordisk's patent for recombinant human growth hormone invalid and unenforceable due to inequitable conduct.

The decision by the U.S. District Court for the District of Delaware deals a blow to the world’s largest insulin maker’s bid to block Israeli generics maker Teva Pharmaceuticals Industries Ltd. and Savient Pharmaceuticals Inc. from selling human growth hormone in the U.S.

The judge said a patent owned by Novo was invalid because of Novo's errors in the application process before...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.